324 related articles for article (PubMed ID: 18505441)
1. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
[TBL] [Abstract][Full Text] [Related]
2. Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Haiping Z; Takayama K; Uchino J; Harada A; Adachi Y; Kura S; Caicun Z; Tsuzuki T; Nakanishi Y
Cancer Gene Ther; 2006 Sep; 13(9):864-72. PubMed ID: 16710346
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
4. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Oshima Y; Sakamoto T; Hisatomi T; Tsutsumi C; Ueno H; Ishibashi T
Gene Ther; 2002 Sep; 9(18):1214-20. PubMed ID: 12215888
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
Daniel C; Schaub K; Amann K; Lawler J; Hugo C
Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
[TBL] [Abstract][Full Text] [Related]
6. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
7. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
Motomura Y; Kanbayashi H; Khan WI; Deng Y; Blennerhassett PA; Margetts PJ; Gauldie J; Egashira K; Collins SM
Am J Physiol Gastrointest Liver Physiol; 2005 Jan; 288(1):G143-50. PubMed ID: 15297261
[TBL] [Abstract][Full Text] [Related]
8. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
[TBL] [Abstract][Full Text] [Related]
9. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis.
Sakamoto T; Ueno H; Sonoda K; Hisatomi T; Shimizu K; Ohashi H; Inomata H
Gene Ther; 2000 Nov; 7(22):1915-24. PubMed ID: 11127579
[TBL] [Abstract][Full Text] [Related]
10. [Inhibiting scar formation in rat cutaneous wounds by blocking TGF-beta signaling].
Liu W; Chua CH; Wu XL; Wang DR; Yin DM; Cui L; Cao YL; Longaker MT
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):31-6. PubMed ID: 12757642
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
[TBL] [Abstract][Full Text] [Related]
12. [Effects of gene therapy with replication-defective adenovirus ericlosing Egr-1 promoter and Smad7 cDNA on irradiation-induced pulmonary fibrosis: experiment with mice].
Wang L; Feng Y; Fu XL; Cai XW
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(40):2847-52. PubMed ID: 17200022
[TBL] [Abstract][Full Text] [Related]
13. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
14. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy.
Ozawa S; Uchiyama K; Nakamori M; Ueda K; Iwahashi M; Ueno H; Muragaki Y; Ooshima A; Yamaue H
Surgery; 2006 Apr; 139(4):563-73. PubMed ID: 16627068
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds.
Kushibiki T; Nagata-Nakajima N; Sugai M; Shimizu A; Tabata Y
J Control Release; 2006 Feb; 110(3):610-7. PubMed ID: 16378654
[TBL] [Abstract][Full Text] [Related]
16. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
18. Influence of C-peptide on early glomerular changes in diabetic mice.
Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y
Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646
[TBL] [Abstract][Full Text] [Related]
19. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
Okada H; Takemura G; Kosai K; Li Y; Takahashi T; Esaki M; Yuge K; Miyata S; Maruyama R; Mikami A; Minatoguchi S; Fujiwara T; Fujiwara H
Circulation; 2005 May; 111(19):2430-7. PubMed ID: 15867170
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis.
Yamada M; Kuwano K; Maeyama T; Yoshimi M; Hamada N; Fukumoto J; Egashira K; Hiasa K; Takayama K; Nakanishi Y
J Clin Pathol; 2007 Aug; 60(8):916-20. PubMed ID: 17018685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
